News
ELUT
3.830
+2.13%
0.080
Press Release: Elutia Announces Strong Third Quarter Results, Accelerating Toward Full Launch of EluPro(R) Antibiotic-Eluting BioEnvelope in 2025
Dow Jones · 7h ago
Press Release: Elutia Announces Strong Third -2-
Dow Jones · 7h ago
Earnings Scheduled For November 14, 2024
Benzinga · 19h ago
Lake Street Remains a Buy on Aziyo Biologics (ELUT)
TipRanks · 3d ago
Weekly Report: what happened at ELUT last week (1104-1108)?
Weekly Report · 3d ago
Weekly Report: what happened at ELUT last week (1028-1101)?
Weekly Report · 11/04 12:14
Weekly Report: what happened at ELUT last week (1021-1025)?
Weekly Report · 10/28 12:03
Elutia to Present at the LD Micro Main Event XVII Conference on Wednesday, October 30
Barchart · 10/23 15:05
Weekly Report: what happened at ELUT last week (1014-1018)?
Weekly Report · 10/21 11:58
Weekly Report: what happened at ELUT last week (1007-1011)?
Weekly Report · 10/14 12:37
Weekly Report: what happened at ELUT last week (0930-1004)?
Weekly Report · 10/07 12:23
Lake Street Sticks to Their Buy Rating for Aziyo Biologics (ELUT)
TipRanks · 10/04 12:45
Weekly Report: what happened at ELUT last week (0923-0927)?
Weekly Report · 09/30 12:13
Weekly Report: what happened at ELUT last week (0916-0920)?
Weekly Report · 09/23 12:12
Elutia Announces New Peer Reviewed Publication Highlighting The Robustness Of EluPro, Company's Antibiotic-Eluting BioEnvelope For Implantable Devices
Benzinga · 09/18 12:09
Weekly Report: what happened at ELUT last week (0909-0913)?
Weekly Report · 09/16 11:58
Weekly Report: what happened at ELUT last week (0902-0906)?
Weekly Report · 09/09 12:13
Elutia Celebrates First Year
Barchart · 09/06 15:23
Aziyo Biologics (ELUT) Receives a Buy from Lake Street
TipRanks · 09/06 12:55
Aziyo Biologics (ELUT) Receives a Buy from Cantor Fitzgerald
TipRanks · 09/06 11:27
More
Webull provides a variety of real-time ELUT stock news. You can receive the latest news about Elutia Inc. through multiple platforms. This information may help you make smarter investment decisions.
About ELUT
Elutia Inc. is a commercial-stage company, which has developed a portfolio of products using both human and porcine tissue. Its portfolio of products spans the Device Protection, Women’s Health and Cardiovascular markets. These products are primarily sold to healthcare providers or commercial partners. In Device Protection, it sells CanGaroo, a biological envelope, that is indicated for use with implantable electronic devices, including cardiac and neurostimulator devices. In Women’s Health, it has developed both patented and proprietary technologies, culminating in the creation of SimpliDerm, a biological matrix designed to leverage the inherent science of natural healing processes. In Cardiovascular, it sells its specialized porcine small intestine submucosa, which is also the tissue used to make CanGaroo, for use as an intracardiac and vascular patch, as well as for pericardial reconstruction. In addition, its TYKE product is designed for use in the neonatal patient population.